Excimer laser-assisted corneal epithelial pattern ablation for corneal cross-linking.

"Conflict of Interest: J. Brekelmans, None; M.M. Dickman, None; S. Verma, SCHWIND Eye‐Tech‐Solutions (E); S. Arba‐Mosquera, SCHWIND Eye‐Tech‐Solutions (E); R. Goldschmidt, None; A. Goz, None; A. Brandis, Steba Biotech (P); T.T.J.M. Berendschot, None; I.E.Y. Saelens, None; A.L. Marcovich, Steba Biotech (P), Yeda Weizmann (P), EyeYon Medical (C, P), Mor Isum (P); A. Scherz, Steba Biotech (C, P); R.M.M.A. Nuijts, Acufocus (S), Alcon (C, L, S), Asico (C), Bausch&Lomb (S), HumanOptics (S), Ophtec (S), ThéaPharma (C)."

"Funding: This work was supported by the Academic Incentive Fund azM/MUMC + and the following foundations: Algemene Nederlandse Vereniging ter Voorkoming van Blindheid, Landelijke Stichting voor Blinden en Slechtzienden and Stichting Steunfonds UitZicht that contributed through UitZicht [grant number 2014‐36]. The funding organizations provided unrestricted grants and had no role in the design or conduct of this research. AS is the inventor of WST‐D licensed to Steba Biotech by ‘Yeda’ with royalties agreement. AB and AM are inventors of WST‐D/NIR treatment with same."